FFM
TYRA icon

Fairmount Funds Management’s Tyra Biosciences TYRA Stock Holding History

Fairmount Funds Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,393,329
Closed -$22.9M – 16
2024
Q1 		$22.9M Hold
1,393,329
– – 2.49% 12
2023
Q4 		$19.3M Hold
1,393,329
– – 2.04% 14
2023
Q3 		$19.2M Sell
1,393,329
-23,669
-2% -$351K 2.31% 15
2023
Q2 		$24.1M Hold
1,416,998
– – 3.4% 9
2023
Q1 		$22.8M Hold
1,416,998
– – 3.92% 11
2022
Q4 		$10.8M Hold
1,416,998
– – 1.71% 15
2022
Q3 		$12.5M Hold
1,416,998
– – 2.19% 16
2022
Q2 		$10.1M Buy
1,416,998
+132,008
+10% +$1.05M 2.32% 19
2022
Q1 		$13.7M Buy
1,284,990
+639,641
+99% +$7.59M 3.25% 12
2021
Q4 		$9.08M Buy
645,349
+146,309
+29% +$2.91M 2.99% 12
2021
Q3 		$8.78M Buy
+499,040
New +$9.54M 3.19% 13

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $76.1M AUM 638.59% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fairmount Funds Management's TYRA Position: Q2 2024 in Review

Fairmount Funds Management sold out of Tyra Biosciences (TYRA) in Q2 2024, closing a stake of 1,393,329 shares — an estimated $22.9M sold.

Fairmount Funds Management first reported a position in TYRA in Q3 2021 and held it in 11 quarters. The position peaked at $24.1M in Q2 2023. 79 funds tracked by Wall St. Rank hold TYRA as of Q2 2024.

  • Fairmount Funds Management reported no remaining Tyra Biosciences position as of Q2 2024 after selling out during the quarter.
  • Fairmount Funds Management sold 1,393,329 Tyra Biosciences shares in Q2 2024, an estimated $22.9M.
  • Fairmount Funds Management first reported a position in Tyra Biosciences in Q3 2021 and held it in 11 quarters.
  • Fairmount Funds Management's Tyra Biosciences position peaked at $24.1M in Q2 2023.
  • 79 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2024.

Based on Fairmount Funds Management's 13F filing for Q2 2024, filed 14 Aug 2024.